title: 4-OH tamoxifen does not interfere with bicalutamide inhibitory effects on human prostatic cancer cells in vitro.
abstract: BACKGROUND
  The present study was aimed at investigating the effects of the co-administration of 4-OH Tamoxifen (4HT) and bicalutamide (BIC) on the human prostate cancer cell line LNCaP in vitro.
  
  
  METHODS
  The LNCaP FGC prostate cancer cell line was grown in vitro within a three-dimensional matrix formed by collagen gel under dihydrotestosterone (DHT) (0.1 nM) stimulation. Cells were incubated in the presence either of BIC at escalating concentrations (1 nM; 100 nM; 10 microM) or 4HT Tamoxifen (10 nM; 100 nM) or both compounds at the different concentrations studied. The cells were incubated for 144 hours, and growth was evaluated in non trypsinised cells by crystal violet vital dye staining assay.
  
  
  RESULTS
  BIC appeared to exert a dose-dependent inhibitory action, with the maximum inhibitory effect achieved by the 10 microM concentration. A comparable inhibitory effect was also observed after exposure to 4HT at both doses tested. No statistically significant interference was observed when BIC was combined with 4HT.
  
  
  CONCLUSIONS
  4HT, even at the higher concentration employed here, showed no major interference with the inhibitory effects of BIC.
authors.affiliation: University of Genoa, Italy. f.boccardo@unige.it
authors.forename: F
authors.initials: F
authors.lastname: Boccardo
authors.forename: D
authors.initials: D
authors.lastname: Medicina
authors.forename: F
authors.initials: F
authors.lastname: Galmozzi
authors.forename: L
authors.initials: L
authors.lastname: Emionite
authors.forename: M
authors.initials: M
authors.lastname: Lo Casto
mesh_terms: D000726:Androgen Antagonists / Q000493:pharmacokinetics / Q000494:pharmacology*; D000813:Anilides / Q000493:pharmacokinetics / Q000494:pharmacology*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000493:pharmacokinetics / Q000494:pharmacology*; D048708:Cell Growth Processes / Q000187:drug effects; D045744:Cell Line, Tumor; D004305:Dose-Response Relationship, Drug; D004347:Drug Interactions; D006801:Humans; D008297:Male; D009376:Neoplasms, Hormone-Dependent / Q000188:drug therapy* / Q000473:pathology; D009570:Nitriles; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000473:pathology; D013629:Tamoxifen / Q000031:analogs & derivatives* / Q000494:pharmacology; D014105:Tosyl Compounds
chemical_list: D000726:Androgen Antagonists; D000813:Anilides; D009570:Nitriles; D014105:Tosyl Compounds; D013629:Tamoxifen; C016601:afimoxifene; C053541:bicalutamide